Bacteriological and clinical studies on NM441

Yoshiro Sawae, Kaoru Okada, Nobuyuki Shimono, Hiroyasu Misumi, Katsuhiko Eguchi, Daisuke Takeda, Yoshiyuki Niho, Takatoshi Inoue, Ikuo Sumida, Kiyoshi Ninomiya, Toshiyuki Ishimaru, Koji Takaki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We performed bacteriological and clinical studies on NM441, a new quinolone antibiotic, with the following results. The antibacterial activities of NM394 against clinical isolates (10 species, 242 strains) were compared with those of ofloxacin (OFLX), ciprofloxacin (CPFX) and tosufloxacin (TFLX). The MIC 90s of NM394 against methicillin-sensitive Staphylococcus aureus (MSSA), methicillin resistant S. aureus (MRSA), Enterococcus faecalis, Klebsiella pneumoniae, Citrobacter freundii, Proteus vulgaris, Escherichia coli, Enterobacter cloacae, Enterobacter aerogenes, Proteus mirabilis and Pseudomonas aeruginosa were 1.56, > 100, 50, ≤0.05, ≤0.05, ≤0.05, 0.10, 0.10, 0.10, 0.20 and 1.56μg/ml, respectively. The activities of NM394 against gram positive bacteria were less potent than those of TFLX, but almost as potent as OFLX and CPFX. The activities against gram negative bacteria were almost as potent as those of CPFX, and more potent than those of OFLX and TFLX. In particular, NM394 showed a high antibacterial activity against P. aeruginosa. NM441 was administered to a total of 22 patients, 20 cases with respiratory tract infections and 2 urinary tract infections, at a daily dose of 200~400mg for 2~21days. Clinical response was excellent in 5 cases, good in 15 and fair in 2. Side effects were observed in a total of 3 cases (13.6%), insomnia in 1, nausea · vomiting in 1 and rash in 1. Abnormal laboratory findings were observed in a total of 3 cases (13.6%), elevations of S-GOT·S-GPT·γ-GTP, S-GOT and S- GOT·S-GPT each in 1 case.

Original languageEnglish
Pages (from-to)329-334
Number of pages6
JournalJapanese Journal of Chemotherapy
Volume44
Issue numberSUPPL. 1
Publication statusPublished - May 7 1996

Fingerprint

tosufloxacin
Ofloxacin
Ciprofloxacin
Pseudomonas aeruginosa
Citrobacter freundii
Proteus vulgaris
Enterobacter aerogenes
Enterobacter cloacae
Proteus mirabilis
Methicillin
Enterococcus faecalis
Quinolones
Klebsiella pneumoniae
Sleep Initiation and Maintenance Disorders
Gram-Positive Bacteria
Methicillin-Resistant Staphylococcus aureus
Guanosine Triphosphate
Exanthema
Gram-Negative Bacteria
Urinary Tract Infections

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Sawae, Y., Okada, K., Shimono, N., Misumi, H., Eguchi, K., Takeda, D., ... Takaki, K. (1996). Bacteriological and clinical studies on NM441. Japanese Journal of Chemotherapy, 44(SUPPL. 1), 329-334.

Bacteriological and clinical studies on NM441. / Sawae, Yoshiro; Okada, Kaoru; Shimono, Nobuyuki; Misumi, Hiroyasu; Eguchi, Katsuhiko; Takeda, Daisuke; Niho, Yoshiyuki; Inoue, Takatoshi; Sumida, Ikuo; Ninomiya, Kiyoshi; Ishimaru, Toshiyuki; Takaki, Koji.

In: Japanese Journal of Chemotherapy, Vol. 44, No. SUPPL. 1, 07.05.1996, p. 329-334.

Research output: Contribution to journalArticle

Sawae, Y, Okada, K, Shimono, N, Misumi, H, Eguchi, K, Takeda, D, Niho, Y, Inoue, T, Sumida, I, Ninomiya, K, Ishimaru, T & Takaki, K 1996, 'Bacteriological and clinical studies on NM441', Japanese Journal of Chemotherapy, vol. 44, no. SUPPL. 1, pp. 329-334.
Sawae Y, Okada K, Shimono N, Misumi H, Eguchi K, Takeda D et al. Bacteriological and clinical studies on NM441. Japanese Journal of Chemotherapy. 1996 May 7;44(SUPPL. 1):329-334.
Sawae, Yoshiro ; Okada, Kaoru ; Shimono, Nobuyuki ; Misumi, Hiroyasu ; Eguchi, Katsuhiko ; Takeda, Daisuke ; Niho, Yoshiyuki ; Inoue, Takatoshi ; Sumida, Ikuo ; Ninomiya, Kiyoshi ; Ishimaru, Toshiyuki ; Takaki, Koji. / Bacteriological and clinical studies on NM441. In: Japanese Journal of Chemotherapy. 1996 ; Vol. 44, No. SUPPL. 1. pp. 329-334.
@article{764a48707b074704be3f135aca81f56a,
title = "Bacteriological and clinical studies on NM441",
abstract = "We performed bacteriological and clinical studies on NM441, a new quinolone antibiotic, with the following results. The antibacterial activities of NM394 against clinical isolates (10 species, 242 strains) were compared with those of ofloxacin (OFLX), ciprofloxacin (CPFX) and tosufloxacin (TFLX). The MIC 90s of NM394 against methicillin-sensitive Staphylococcus aureus (MSSA), methicillin resistant S. aureus (MRSA), Enterococcus faecalis, Klebsiella pneumoniae, Citrobacter freundii, Proteus vulgaris, Escherichia coli, Enterobacter cloacae, Enterobacter aerogenes, Proteus mirabilis and Pseudomonas aeruginosa were 1.56, > 100, 50, ≤0.05, ≤0.05, ≤0.05, 0.10, 0.10, 0.10, 0.20 and 1.56μg/ml, respectively. The activities of NM394 against gram positive bacteria were less potent than those of TFLX, but almost as potent as OFLX and CPFX. The activities against gram negative bacteria were almost as potent as those of CPFX, and more potent than those of OFLX and TFLX. In particular, NM394 showed a high antibacterial activity against P. aeruginosa. NM441 was administered to a total of 22 patients, 20 cases with respiratory tract infections and 2 urinary tract infections, at a daily dose of 200~400mg for 2~21days. Clinical response was excellent in 5 cases, good in 15 and fair in 2. Side effects were observed in a total of 3 cases (13.6{\%}), insomnia in 1, nausea · vomiting in 1 and rash in 1. Abnormal laboratory findings were observed in a total of 3 cases (13.6{\%}), elevations of S-GOT·S-GPT·γ-GTP, S-GOT and S- GOT·S-GPT each in 1 case.",
author = "Yoshiro Sawae and Kaoru Okada and Nobuyuki Shimono and Hiroyasu Misumi and Katsuhiko Eguchi and Daisuke Takeda and Yoshiyuki Niho and Takatoshi Inoue and Ikuo Sumida and Kiyoshi Ninomiya and Toshiyuki Ishimaru and Koji Takaki",
year = "1996",
month = "5",
day = "7",
language = "English",
volume = "44",
pages = "329--334",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Bacteriological and clinical studies on NM441

AU - Sawae, Yoshiro

AU - Okada, Kaoru

AU - Shimono, Nobuyuki

AU - Misumi, Hiroyasu

AU - Eguchi, Katsuhiko

AU - Takeda, Daisuke

AU - Niho, Yoshiyuki

AU - Inoue, Takatoshi

AU - Sumida, Ikuo

AU - Ninomiya, Kiyoshi

AU - Ishimaru, Toshiyuki

AU - Takaki, Koji

PY - 1996/5/7

Y1 - 1996/5/7

N2 - We performed bacteriological and clinical studies on NM441, a new quinolone antibiotic, with the following results. The antibacterial activities of NM394 against clinical isolates (10 species, 242 strains) were compared with those of ofloxacin (OFLX), ciprofloxacin (CPFX) and tosufloxacin (TFLX). The MIC 90s of NM394 against methicillin-sensitive Staphylococcus aureus (MSSA), methicillin resistant S. aureus (MRSA), Enterococcus faecalis, Klebsiella pneumoniae, Citrobacter freundii, Proteus vulgaris, Escherichia coli, Enterobacter cloacae, Enterobacter aerogenes, Proteus mirabilis and Pseudomonas aeruginosa were 1.56, > 100, 50, ≤0.05, ≤0.05, ≤0.05, 0.10, 0.10, 0.10, 0.20 and 1.56μg/ml, respectively. The activities of NM394 against gram positive bacteria were less potent than those of TFLX, but almost as potent as OFLX and CPFX. The activities against gram negative bacteria were almost as potent as those of CPFX, and more potent than those of OFLX and TFLX. In particular, NM394 showed a high antibacterial activity against P. aeruginosa. NM441 was administered to a total of 22 patients, 20 cases with respiratory tract infections and 2 urinary tract infections, at a daily dose of 200~400mg for 2~21days. Clinical response was excellent in 5 cases, good in 15 and fair in 2. Side effects were observed in a total of 3 cases (13.6%), insomnia in 1, nausea · vomiting in 1 and rash in 1. Abnormal laboratory findings were observed in a total of 3 cases (13.6%), elevations of S-GOT·S-GPT·γ-GTP, S-GOT and S- GOT·S-GPT each in 1 case.

AB - We performed bacteriological and clinical studies on NM441, a new quinolone antibiotic, with the following results. The antibacterial activities of NM394 against clinical isolates (10 species, 242 strains) were compared with those of ofloxacin (OFLX), ciprofloxacin (CPFX) and tosufloxacin (TFLX). The MIC 90s of NM394 against methicillin-sensitive Staphylococcus aureus (MSSA), methicillin resistant S. aureus (MRSA), Enterococcus faecalis, Klebsiella pneumoniae, Citrobacter freundii, Proteus vulgaris, Escherichia coli, Enterobacter cloacae, Enterobacter aerogenes, Proteus mirabilis and Pseudomonas aeruginosa were 1.56, > 100, 50, ≤0.05, ≤0.05, ≤0.05, 0.10, 0.10, 0.10, 0.20 and 1.56μg/ml, respectively. The activities of NM394 against gram positive bacteria were less potent than those of TFLX, but almost as potent as OFLX and CPFX. The activities against gram negative bacteria were almost as potent as those of CPFX, and more potent than those of OFLX and TFLX. In particular, NM394 showed a high antibacterial activity against P. aeruginosa. NM441 was administered to a total of 22 patients, 20 cases with respiratory tract infections and 2 urinary tract infections, at a daily dose of 200~400mg for 2~21days. Clinical response was excellent in 5 cases, good in 15 and fair in 2. Side effects were observed in a total of 3 cases (13.6%), insomnia in 1, nausea · vomiting in 1 and rash in 1. Abnormal laboratory findings were observed in a total of 3 cases (13.6%), elevations of S-GOT·S-GPT·γ-GTP, S-GOT and S- GOT·S-GPT each in 1 case.

UR - http://www.scopus.com/inward/record.url?scp=15844386164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15844386164&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:15844386164

VL - 44

SP - 329

EP - 334

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - SUPPL. 1

ER -